News

At its 2024 Awards Gala, held June 20, 2024, at The Plaza Hotel in New York City to honor kidney donors and the achievements of the American transplant industry, the National Kidney Registry presented the Terasaki Medical Innovation Award to Dr. Joe Leventhal. The Terasaki Medical Innovation Award is given to an individual or organization…

Immunofree, a company advancing stem cell technology to eliminate the need for immunosuppressive medications in transplant patients, congratulates Dr. Robert Montgomery on winning the prestigious Jacobson Innovation Award from the American College of Surgeons. The award was presented to Dr. Montgomery on June 14, 2024, at the Chicago History Museum at a dinner in his…

Surgeons at NYU Langone Health performed the first combined mechanical heart pump and gene-edited pig kidney transplant surgery.

In the fall of 2021, Gabriel Arias felt like his body was “rotting from the inside.” He was diagnosed with acute myeloid leukemia, a form of blood cancer so aggressive that doctors had him hospitalized the day of his biopsy.

Drs. Ephraim Fuchs and Joseph Leventhal were among the esteemed speakers at the 6th International Sam Strober Workshop on Clinical Immune Tolerance Research, which was held March 25–26, 2024, at Oxford University’s Exeter College. This year’s event, with a focus on autoimmunity, aimed to expand the dialogue surrounding transplantation tolerance and autoimmune regulation. Drs. Fuchs…

The National Kidney Foundation (NKF) announced today its latest strategic investment through its NKF Innovation Fund. The fund will support ImmunoFree, a pioneering biomedical company dedicated to reshaping the landscape of organ transplantation by eliminating the need for immunosuppressive medications.

Today, ImmunoFree, Inc. announced that Dr. Ephraim Fuchs has been appointed the Chief Medical Officer of ImmunoFree. In his role as CMO, Dr. Fuchs will oversee all medical and scientific affairs of the company and be responsible for the development of the ImmunoFree tolerance protocol for the 1,000,000+ transplant recipients worldwide who can benefit from…

While kidney transplantation has traditionally required recipients to take immunosuppressive drugs for the remainder of their lives to prevent organ rejection, a new study offers hope for a treatment that may enable transplant recipients to take lower dosages of these drugs, or even none at all. The study, published in Clinical Transplantation in August 2023,…

ImmunoFree, Inc. announced today that it has acquired all rights to FCR001, a cellular therapy product, and the sponsorship of the FREEDOM-1 Study formerly owned by Talaris Therapeutics (TALS). ImmunoFree has assumed all financial and regulatory responsibilities related to these clinical trials. Effective immediately, ImmunoFree will oversee all remaining close-out activities and the shutdown of…

Today the National Kidney Registry announced the activation of its 2,000th patient microsite. The microsite program provides free websites and coaching to transplant patients seeking a living donor. The theory behind the microsite program is that if a patient can direct potential donors to a website that effectively tells their story, they will connect with…